Calvitalis

Quick links to important sections

Calvitalis

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Calvitalis

Property Description
Active ingredient Pyridoxine Hydrochloride, Calcium lactate gluconate, 9 total vitamins
Form Syrup (Oral Solution)
Pharmacological class Multivitamins with Minerals
Common use Prophylaxis of vitamin and calcium deficiencies
Origin Combination of synthetic and naturally-derived micronutrients

Calvitalis is a commercially recognized nutritional supplement classified as a Multivitamin with Minerals combination product, intended for Oral administration. Manufactured in the United Arab Emirates by Gulf Pharmaceutical Industries - JULPHAR, it is specifically formulated as a palatable syrup or oral solution, a distinctive feature that supports administration to patient groups who may struggle with solid dosage forms.

Essential Constituents and General Purpose

The preparation is a multi-component blend of ten essential constituents. These include key B group vitamins like Pyridoxine Hydrochloride (Vitamin B6), which is recognized for its critical coenzyme function in numerous metabolic activities. The formula supplies elements integral to the body’s metabolic and neurological systems.

The core of the formula provides the mineral Calcium through Calcium lactate gluconate, a source known for its bioavailability. Crucially, the preparation also includes Cholecalciferol (Vitamin D3), which is essential for regulating intestinal absorption of calcium. This pairing demonstrates a design tailored to maximize the structural benefit of the mineral. The general purpose of the formulation is centered on prophylaxis—the systemic prevention of combined vitamin deficiencies and calcium deficiencies, a typical use scenario often applied during periods of rapid growth. By supplying these necessary elements, the preparation supports overall vitality and the maintenance of healthy bone structure.

Regulatory References

  1. National Institutes of Health Fact Sheet on Vitamin D

What side effects are possible with Calvitalis?

Possible side effects and safety information

The safety profile of this multi-component preparation is defined by regulatory documents classifying adverse reactions according to frequency and affected physiological systems. All documented side effects and safety constraints are derived from official government prescribing information for the active constituents, including Pyridoxine Hydrochloride and Calcium lactate gluconate.

Officially Documented Adverse Reactions

Adverse effects are broadly categorized across several System-Organ Classes (SOCs), with the most frequent occurrences relating to the digestive and metabolic systems.

Classification System-Organ Class Documented Adverse Reaction(s)
Uncommon Metabolism and Nutrition Disorders Hypercalcaemia (elevated blood calcium), Hypercalciuria (excessive urinary calcium excretion)
Rare Gastrointestinal Disorders, Immune System Nausea, vomiting, constipation, diarrhoea, hypersensitivity reactions
Very Rare Immune System Disorders Severe systemic allergic reactions

Serious Safety Considerations

Official regulatory sources note that prolonged administration of high doses of Pyridoxine (Vitamin B6) is specifically associated with the risk of developing Peripheral Neuropathy, a serious neurological adverse reaction. Additionally, sustained Hypercalciuria may lead to the formation of renal stones (nephrolithiasis).

Safety Restrictions and Special Populations

Contraindications listed in regulatory documents specify that the preparation must not be used in individuals with pre-existing conditions such as Hypercalcaemia, Hypercalciuria, or a history of Nephrolithiasis. Caution is advised, and monitoring of serum calcium levels and renal function is required in patients with pre-existing renal impairment or a history of kidney stones. These restrictions are established to manage risks associated with the metabolism of calcium and Vitamin D components.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information mandates that emergency medical attention must be sought immediately following any known or suspected overdose of this multivitamin and mineral product. Immediate contact with emergency services or a national poison control center is required.

Overdose presentations primarily involve two major toxicity profiles derived from the active components. Toxicity from Pyridoxine may present as neurological symptoms, including peripheral sensory neuropathy, ataxia, numbness, and tingling. Regulator-documented severe outcomes associated with Pyridoxine toxicity include the potential for permanent nerve damage.

Over-ingestion of Calcium and Vitamin D can lead to hypercalcemia, resulting in symptoms such as nausea, vomiting, confusion, and headache. The documented life-threatening consequences of severe hypercalcemia include cardiac arrhythmias and acute kidney failure.

Management is focused on symptomatic and supportive care, requiring the discontinuation of the product. No specific antidote is known for Pyridoxine toxicity. Hospital monitoring is required in severe cases, including assessment of vital signs, laboratory tests, and ECG monitoring. A specific overdose risk is documented for patients with pre-existing impaired kidney function, which increases the likelihood of severe hypercalcemia.

Therapeutic Uses of Calvitalis

What Calvitalis Treats: Main Uses and Benefits

Calvitalis is commonly used to help with the systemic prevention of deficiencies in essential vitamins and minerals, particularly Calcium and Vitamin D. Adequate intake of these micronutrients supports maintaining bone strength and may assist with easing the risk of osteoporosis, which is relevant to the supplement's core therapeutic domain.

Therapeutic Domains and Benefits

The preparation is applied in addressing conditions characterized by deficiency patterns, which include skeletal fragility, low bone mineral density, and neuromuscular irritability. It helps address symptom clusters related to muscle cramps and spasms and supports general well-being during periods of systemic imbalance. This therapeutic approach is commonly used to help with the needs of specific patient groups, such as children and adolescents during periods of rapid growth, or to support the elevated needs of pregnant and nursing women.

“The primary goal of this formulation is to provide support that helps ease the overall symptom burden in situations where functional stability becomes affected due to nutritional gaps.”


Quick Fact: Support for Neuromuscular Irritability The supplement is commonly used to help with symptoms related to heightened physiological activity (like spasms), providing supportive relief when symptoms interfere with daily functioning.

Regulatory References

  1. NIH MedlinePlus overview on Calcium and Vitamin D

Eligibility and Restrictions for Use

Who Must Not Use Calvitalis (Contraindications)

Official regulatory documents mandate that Calvitalis syrup is strictly contraindicated for specific patient populations. The medicine must not be used by individuals who have a known allergy to any of its components.

Additionally, due to the calcium and vitamin D content, use is prohibited in patients diagnosed with:

  • Hypercalcaemia: An excessive amount of calcium in the blood.
  • Hypercalciuria: An excessive amount of calcium in the urine.

Established and Restricted Use

The official eligibility profile defines specific age groups and conditions for permitted use:

  • Established Eligibility: Use is officially established for the Pediatric population (children below and above four years of age) and the Adult population.
  • Pregnancy and Lactation: Use is generally permitted at the recommended daily dosage. However, this dosage must not be exceeded during pregnancy to ensure Vitamin A intake remains below the specified regulatory limit.
  • Conditional Restrictions: Patients with renal calculus (kidney stones) or Boeck's disease (sarcoidosis) are restricted from using the syrup for long periods or in doses higher than specified, except under the guidance of a healthcare professional.

What should I know about interactions with other medicines?

Calvitalis Interactions with other medicines and products

Documented Interactions Affecting Drug Exposure

The interaction profile for this multivitamin and mineral preparation is defined by its calcium and pyridoxine components, as documented in official regulatory sources.

Interacting Substance Category Official Interaction Result
Oral Antibiotics (Tetracyclines, Quinolones) Decreased absorption and reduced blood concentration of the antibiotic.
Bisphosphonates, Levothyroxine Decreased absorption and reduced systemic exposure of the co-administered drug.

To mitigate absorption-reducing interactions, regulatory guidance requires that the administration of oral antibiotics, bisphosphonates, and thyroid medications must be separated by several hours from the multivitamin/mineral product.

Pharmacodynamic and Efficacy-Altering Interactions

The calcium component carries a risk of pharmacodynamic synergism with cardiovascular agents. Co-administration with Cardiac Glycosides (e.g., Digoxin) may increase the arrhythmogenic and cardiotoxic activities of the glycoside. Furthermore, Pyridoxine (Vitamin B6) antagonizes the action of Levodopa (when taken without Carbidopa), which reduces the therapeutic effect of Levodopa.

Contraindicated Combinations and Restrictions

Official documents state that co-administration with other Vitamin A or Vitamin D preparations is contraindicated due to the additive risk of hypervitaminosis or hypercalcaemia. A mandatory, population-specific contraindication is also documented: intravenous calcium-containing products must not be co-administered with intravenous Ceftriaxone in neonates (28 days of age or younger) due to precipitation risk.

Mechanism of Action

Calvitalis contains a combination of calcium salts and multiple vitamins, including Cholecalciferol (Vitamin D3) and Thiamine (Vitamin B1). The mechanism of action is primarily defined by its active constituents.

The pharmacodynamic action of Cholecalciferol relies on its sequential metabolic conversion to Calcitriol (1,25-dihydroxyvitamin D3) in the liver and kidney. Calcitriol acts as a ligand/agonist for the nuclear Vitamin D Receptor (VDR), which is a member of the steroid hormone receptor superfamily. Upon ligand binding, the activated VDR forms a heterodimer with the Retinoid X Receptor (RXR). This complex translocates to the nucleus where it binds to specific Vitamin D-Responsive Elements (VDREs) in the promoter region of target genes. This interaction functions as a transcriptional regulator, leading to the modified expression of genes involved in systemic calcium and phosphate homeostasis. Downstream cascades include enhanced intestinal absorption of dietary calcium and phosphate, coupled with modulation of renal tubular reabsorption and bone turnover, collectively resulting in systemic elevation of plasma calcium concentration.

Separately, Thiamine acts as a precursor for the cofactor Thiamine Pyrophosphate (TPP). TPP is essential for the enzymatic function of three primary metabolic enzymes: pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, and branched-chain alpha-keto acid dehydrogenase. Its interaction with these enzymes facilitates cellular energy generation by acting in the catabolism of carbohydrates and branched-chain amino acids, thereby supporting the cellular process of mitochondrial oxidative metabolism.

Dosage and Administration Information

How to Use Calvitalis

Calvitalis is designated for Oral administration as a Syrup (Oral Solution). The dosage is standardized into a once daily regimen for all patient groups, intended for its prophylactic use.


Dosage and Frequency

The established regimen is differentiated by age, with doses measured in the standardized volume of a teaspoonful (5 mL). This allows for volumetric administration of the oral solution.

Age Group Standard Daily Dose
Children below 4 years 1 teaspoonful (5 mL) once daily
Children above 4 years & Adults 2 teaspoonfuls (10 mL) once daily

High-Level Usage Principles

Calvitalis is typically used as a tonic and for the prophylaxis (prevention) of vitamin and calcium deficiencies, establishing a pattern of supportive, long-term use.

In specific populations, caution is emphasized regarding dose limits. For instance, in pregnant and lactating women, it is recommended not to exceed the daily dosage due to specific considerations related to potential excessive Vitamin A intake.

When administering the solution, a harmless slight yellowish discoloration of the urine may be observed. This is a recognized and harmless physiological effect related to the riboflavin (Vitamin B2) content.

Recent Clinical Evidence

Calvitalis: Recent Clinical Evidence


Evidence for Prophylaxis of Vitamin and Calcium Deficiencies

Research on preventing nutritional gaps primarily relies on extensive systematic reviews and Randomized Controlled Trials (RCTs) that have explored the effect of key micronutrients, such as Calcium, Vitamin D, and B vitamins, either individually or in simple pairs. These studies were used in research exploring how deficiencies or imbalances change over time. Outcomes measured included serum levels of essential biomarkers, such as 25-hydroxyvitamin D (25(OH)D) and serum calcium, which are used to monitor physiological status. Studies reported measurements of biomarker levels. Concentrations related to essential nutrition were observed in populations receiving supplementation, indicating that the research context is deficiency prevention.

Research Examining Healthy Bone Structure and Low Bone Mineral Density

This area of evidence centers on components that are studied for their role in bone health. Research examined interventional trials and meta-analyses, typically in populations with low Bone Mineral Density (BMD) or those in a phase of life requiring high bone mass accrual. Study outcomes examined included the direct measurement of BMD and Bone Mineral Content (BMC), along with monitoring biological markers related to bone turnover.

Studies Examining Symptoms Related to Neuromuscular Irritability

The research base for the supportive role of this supplement in conditions involving outcomes related to systemic or functional imbalance, such as muscle cramps and spasms, largely comes from studies on individual components like Pyridoxine (Vitamin B6). The studies explored short-term symptom changes using patient-reported outcomes describing perceived discomfort. Pooled data from multiple trials described observed changes in the patient-reported frequency or severity scores of symptoms following the use of Pyridoxine supplementation.

Research Gaps and What Remains Uncertain About the Formulation

The available data primarily stem from research on the individual or paired ingredients (e.g., Vitamin D and Calcium), rather than dedicated, large-scale RCTs of the specific nine-vitamin and multi-mineral syrup formulation. This means conclusions about the full product are often based on extrapolation from the known science of its components. Furthermore, the certainty remains low regarding the effects of routine multi-component supplementation in generally healthy populations without clear deficiency, where existing evidence may be insufficient.

Key Studies & References

  1. Vitamin B6 Fact Sheet for Consumers - NIH Office of Dietary Supplements

Frequently Asked Questions (FAQ)

Common questions about Calvitalis (FAQ)

Q: Is Calvitalis considered a vitamin or a medication?

A: According to regulatory bodies, preparations like this multivitamin and mineral supplement are generally classified as a dietary supplement, which falls under a different regulatory category than conventional prescription drug products. This classification is consistent with its intended use for the prophylaxis (prevention) of vitamin and calcium deficiencies.

Q: Are there any long-term effects associated with taking Calvitalis?

A: Official prescribing information addresses potential risks associated with prolonged, high-dose use of its constituents. Long-term administration of high doses of Pyridoxine (Vitamin B6) has been associated with the risk of developing Peripheral Neuropathy, a serious neurological condition. Additionally, sustained high levels of calcium in the urine may lead to the formation of renal (kidney) stones.

Q: What are the signs of a rare but serious reaction to Calvitalis?

A: Serious allergic reactions, though rare, can occur. Signs to watch for include severe swelling of the face, lips, tongue, or throat, difficulty breathing, wheezing, or widespread rash and hives. Official safety documentation advises that these signs are considered medical emergencies.

Q: Can Calvitalis make existing medical conditions worse?

A: Regulatory documents list several pre-existing conditions where the product should not be used because its components may worsen a metabolic imbalance. This includes Hypercalcaemia (excessive calcium in the blood) and Hypercalciuria (excessive calcium in the urine), as the calcium and Vitamin D content could exacerbate these issues.

Q: What precautions are listed for patients who have liver problems and want to use Calvitalis?

A: While the full product may not have a specific liver warning, the official safety information for its constituent, Pyridoxine (Vitamin B6), often advises caution for individuals with pre-existing liver conditions. The official safety information generally indicates that pre-existing liver issues should be disclosed to a healthcare professional.

Q: Can Calvitalis cause weight gain?

A: Weight gain is not listed as a commonly reported adverse reaction in the official product information. However, information on its component Pyridoxine (Vitamin B6) sometimes lists related gastrointestinal issues such as loss of appetite.

Q: Is it normal to feel tired after starting Calvitalis?

A: Tiredness or fatigue is not typically listed as a common or specific adverse reaction for this multivitamin/mineral combination in official regulatory documents.

Q: Does Calvitalis require a special diet or should certain foods be avoided while taking it?

A: Official guidance on the calcium component advises that certain foods can affect absorption. Foods high in oxalic acid (like spinach or rhubarb) or phytic acid (found in whole grains) may decrease the amount of calcium absorbed. Some information also notes that grapefruit juice may affect the metabolism of Vitamin D components.

Q: Does Calvitalis affect blood pressure readings?

A: Official warnings for the product focus on a risk of increased cardiotoxic activity when the calcium component is co-administered with certain cardiovascular agents, specifically Cardiac Glycosides. The documents do not generally state a direct effect on routine blood pressure readings.

Q: Can Calvitalis affect sleep patterns?

A: Official safety information for the core vitamin and mineral components typically does not list sleep problems or insomnia as known adverse reactions.

Q: Is it necessary to take Calvitalis at the same time every day?

A: The regimen is officially designated for once daily use, establishing a consistent frequency of intake. However, official labels generally do not mandate taking the dose at a specific, exact time each day.

Q: Is Calvitalis chemically related to any other known medications?

A: The active ingredients in this supplement are essential human nutrients. Constituents such as Cholecalciferol (Vitamin D3) and Thiamine (Vitamin B1) are utilized in numerous other medicinal preparations, both single-ingredient and combination products.

Q: What is the risk of dependence or withdrawal with Calvitalis?

A: Official regulatory documents for this multivitamin and mineral preparation and its components do not contain any warnings or statements regarding the risk of physical dependence or withdrawal symptoms.

Q: Can I take Calvitalis if I am also taking herbal supplements?

A: Official safety resources commonly advise that patients are generally expected to inform their healthcare provider about all substances they are using, including prescription medicines, over-the-counter products, vitamins, minerals, herbal products, and other supplements. This disclosure helps to ensure all potential interactions are reviewed.

Q: Are there any known interactions between Calvitalis and alcohol?

A: While a direct interaction with the product is not commonly cited, official information on the component Pyridoxine (Vitamin B6) notes that the consumption of large amounts of alcohol may be associated with reduced levels of the vitamin in the body.

Q: Does Calvitalis cause dry mouth or changes in appetite?

A: Official safety information for the component Pyridoxine (Vitamin B6) sometimes lists loss of appetite as a reported gastrointestinal issue. However, dry mouth is not typically listed as an adverse reaction in the official documents.

Q: Is it safe to drive or operate machinery while taking Calvitalis?

A: Official regulatory documents for this type of multivitamin and mineral preparation typically do not contain warnings or statements advising users to restrict driving or operating machinery.

Q: Is Calvitalis taken with or without food?

A: Official administration information concerning the calcium component suggests that taking the product with food may help to increase the absorption of calcium.

How should Calvitalis be stored and disposed of?

How to Store and Dispose of Calvitalis?

The storage and disposal of Calvitalis oral solution must adhere strictly to official regulatory guidelines to maintain its stability and ensure public safety.


Official Storage Conditions

Condition Requirement
Temperature Store below 25 C; avoid excessive heat.
Environment Protect from light and moisture; Do not freeze the solution.
Packaging Keep the bottle tightly closed and store it in the original container.

Handling and Disposal

The medicine must be kept out of the sight and reach of children to prevent accidental ingestion. Since Calvitalis is an oral solution, once the bottle is opened, it has a limited in-use shelf-life as specified on the label, after which it must be discarded. Disposal of unused or expired product must follow local pharmaceutical waste regulations, often requiring return to a drug take-back program. It is prohibited to dispose of the product in household wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Calvitalis found in:

A-Z Index: